Literature DB >> 11045038

[PADAM from the urologic viewpoint].

G Ludwig1.   

Abstract

PADAM stands for partial androgen deficiency in the aging male, and it is currently diagnosed with a testosterone level below 3 ng/ml (300 ng/dl or 12 nmol/l), and with symptoms varying according to the individual. The symptoms are a reduction or even loss of libido, a decline in muscle mass and strength, enhancement of visceral fatty tissue-padding, dryness of the skin, apathy, tiredness and distortion of mood right up to depression, and ostalgia due to osteoporosis. Before starting any form of hormonal substitution, which is only indicated if clinical symptoms and testosterone deficiency correlate, it is absolutely essential to exclude prostate cancer by using clinical evaluation and PSA values. Close PSA monitoring is necessary during testosterone substitution. In more than 95% of all patients with erectile dysfunction, the cause is not testosterone deficiency. Even a decreased level of dehydroepiandrosterone (DHEA) in an elderly male needs no replacement. There is also no indication for estradiol therapy in men--except in the rare case of aromatase deficiency.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11045038     DOI: 10.1007/s001200050381

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  5 in total

1.  [When is there something wrong with the "aging male"? The older man as the focus of urologists].

Authors:  W Weidner; G Ludwig
Journal:  Urologe A       Date:  2004-09       Impact factor: 0.639

2.  [LOH (late-onset hypogonadism) or the "aging male"].

Authors:  H Sperling; F Jockenhövel; W Stackl; F-M Köhn; G Ludwig
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

Review 3.  [Testosterone substitution therapy in prostate cancer].

Authors:  A Kaminsky; H Sperling
Journal:  Urologe A       Date:  2011-08       Impact factor: 0.639

4.  Case scenarios in androgen deficiency.

Authors:  Andrew McCullough
Journal:  Rev Urol       Date:  2003

5.  [Testosterone replacement therapy for prostate cancer].

Authors:  A Kaminsky; H Sperling
Journal:  Urologe A       Date:  2010-01       Impact factor: 0.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.